Eli Lilly and Company (LLY) stock has risen 16.1% over the last 12 months and 15.7% in 2017 year-to-date. Analysts are estimating that the stock might fall 8.3% over the next 12 months. They’re estimating a 12-month target price of $92.14 per share compared to $85.07 on December 22, 2017.
The above chart shows analysts’ recommendations for Eli Lilly stock over the last 12 quarters.
As of December 26, 2017, there are 24 analysts tracking Eli Lilly stock. Fourteen of them have recommended a “buy” for the stock, nine have recommended a “hold,” and one has recommended a “sell.” The consensus rating for Eli Lilly stands at 2.25, which represents a “buy” for long-term investors and value investors. Changes in analyst recommendations and estimates for the target price are based on changes in the trends of the stock as well as developments and changes in the company’s performance.
The SPDR S&P 500 ETF (SPY) holds 13.6% of its total investments in healthcare companies. SPY has 0.4% of its total investments in Eli Lilly (LLY), 0.4% in Celgene (CELG), 0.2% in Allergan (AGN), and 0.2% in Vertex Pharmaceuticals (VRTX).